Rollover Equity Calculator: What Your Rolled Stake Could Be Worth at the Second Sale
Your rolled stake is worth your ownership share of the equity left at the second sale. That equity is exit EBITDA times the exit multiple, less remaining debt and the management pool. In our hypothetical $30 million dental deal, a $6 million roll becomes about $16.2 million in five years. That is a 2.70x return and a 21.9% IRR. Put the sponsor's cash in an 8% preferred and hold EBITDA flat, and the same roll returns about half its cost.
Estimate only. Educational, not investment advice.
Data as of November 20, 2026. Each market figure names its source, population and period beside it. All worked examples are hypothetical and are our arithmetic.
The 9 inputs and where to find each one
| Input | What to enter | Where to find it |
|---|---|---|
| Entry enterprise value | Headline price for 100% of the business, before debt payoff and fees | LOI or purchase agreement |
| Entry EBITDA multiple | Price divided by the adjusted EBITDA the buyer underwrote | LOI, banker's teaser, quality of earnings report |
| Debt at close (% of EV) | Acquisition debt as a share of enterprise value | Sources and uses table, credit commitment letter |
| Rollover amount | Dollar value of the equity you take instead of cash | LOI rollover clause, contribution agreement |
| Annual EBITDA growth | Expected yearly EBITDA growth, organic plus add-ons | Sponsor's model, your own budget |
| Years to second sale | Expected hold until the sponsor sells | Sponsor's fund strategy and hold history |
| Exit multiple | EBITDA multiple you expect at the second sale | Comparable sponsor-to-sponsor deals, benchmarks below |
| Debt paid down by exit | Share of entry debt repaid before the exit | Sponsor's model, credit agreement amortization and cash sweep terms |
| Management incentive pool | Effective share of exit equity paid to management. For profits interests above a threshold, use the conversion in the adjustments section | Draft LLC agreement, incentive plan term sheet |
Three assumptions sit under every output. Your rollover is common equity bought at the same unit price as the sponsor's cash. The sponsor's cash and your roll make up all of the entry equity. Paydown is a single percentage you choose. If co-investors, management or equity-funded fees add units at close, compute ownership as your units divided by total units. If the credit agreement allows new borrowing for acquisitions, paydown can turn negative. Run 0% paydown as a floor.
The 9 outputs, defined exactly
| Output | Exact definition |
|---|---|
| Entry EBITDA | Entry EV ÷ entry multiple |
| Entry equity | Entry EV × (1 − debt %) |
| Ownership % | Rollover amount ÷ entry equity |
| Exit EBITDA | Entry EBITDA × (1 + growth)^years |
| Exit EV | Exit EBITDA × exit multiple |
| Exit equity | (Exit EV − entry debt × (1 − paydown %)) × (1 − effective management pool %) |
| Rolled stake value | Ownership % × exit equity |
| MOIC | Rolled stake value ÷ rollover amount |
| IRR | MOIC^(1 ÷ years) − 1, assuming no interim distributions |
All outputs are pre-tax and before exit fees. The tax and fee sections below show how to adjust.
Worked example: a $30 million dental platform sale with $6 million rolled
Example (hypothetical, our arithmetic). A multi-site dental group with $3 million of EBITDA sells to a sponsor at 10x. The sponsor funds $15 million of debt and $9 million of cash equity. You roll $6 million into the same class of units at $1.00 per unit. That gives 15,000,000 units at close, of which you hold 6,000,000. Your roll is 20% of the price and 40% of the equity. Management receives profits interests that take 8% of every dollar of equity value above a $15 million threshold, the entry equity value. Debt is 30% repaid by exit. Transaction fees are ignored.
Dental is a high-volume target. Of the 1,029 PE-backed U.S. healthcare deals the Private Equity Stakeholder Project tracked in 2025 (PitchBook and LevinPro HC data), 149 were in dental, and 95% of those were add-ons by PE-owned platforms. Sikich's Q3 2026 update gives indicative 2026 ranges of 9 to 11x EBITDA for DSO platforms and 5 to 8x for dental add-ons, so 10x is a platform price.
| Step | Calculation | Result |
|---|---|---|
| Entry EBITDA | $30,000,000 ÷ 10 | $3,000,000 |
| Debt at close | $30,000,000 × 50% | $15,000,000 (5.0x EBITDA) |
| Entry equity | $9,000,000 sponsor + $6,000,000 roll | $15,000,000 (15,000,000 units at $1.00) |
| Ownership | 6,000,000 ÷ 15,000,000 units | 40% |
| Exit EBITDA | $3,000,000 × 1.10^5 | $4,831,530 |
| Exit EV | $4,831,530 × 11 | $53,146,830 |
| Debt at exit | $15,000,000 × (1 − 30%) | $10,500,000 |
| Equity before pool | $53,146,830 − $10,500,000 | $42,646,830 |
| Profits interests | 8% × ($42,646,830 − $15,000,000) | $2,211,746 |
| Equity to capital holders | $42,646,830 − $2,211,746 | $40,435,084 |
| Rolled stake value | $40,435,084 × 40% | $16,174,033 |
| MOIC | $16,174,033 ÷ $6,000,000 | 2.70x |
| IRR | 2.70^(1/5) − 1 | 21.9% |
The pool takes 5.19% of exit equity here, not 8%. Entering a flat 8% pool in the calculator gives $15,694,033 and 2.62x, which understates the stake by about $480,000. Enter 5.19% to reproduce the table within rounding. This pool design is one common form. Some plans use a catch-up, tiered thresholds or a hurdle set above entry value, and each changes the dollar figure. Read the mechanics in the draft LLC agreement and rerun the conversion.
The 5.0x leverage is in line with the broader market. PitchBook data reported by Sikich puts 2025 entry leverage at 5.2x EBITDA for the median PE-backed U.S. healthcare services buyout. That population spans all services subsectors and larger companies, with a median implied EBITDA of about $33 million, so treat it as context for a $3 million dental platform, not as a benchmark.
How each assumption moves the result
Hypothetical, our arithmetic. Every row holds the other base case inputs, including 30% paydown and the profits-interest pool with its $15 million threshold.
| Scenario | Rolled stake value | MOIC | IRR |
|---|---|---|---|
| Base case (11x exit, 5 years) | $16,174,033 | 2.70x | 21.9% |
| Exit at 10x, flat to entry | $14,396,030 | 2.40x | 19.1% |
| Exit at 9x, one turn down | $12,618,027 | 2.10x | 16.0% |
| 5% growth instead of 10% | $12,115,163 | 2.02x | 15.1% |
| No debt paydown | $14,518,033 | 2.42x | 19.3% |
| 7-year hold, 10% growth continues, paydown held at 30% | $20,281,220 | 3.38x | 19.0% |
| 7-year hold, EBITDA flat after year 5, paydown held at 30% | $16,174,033 | 2.70x | 15.2% |
In this deal, halving growth costs more than losing two turns of multiple. Test the growth assumption first. A longer hold with continued growth raises MOIC but lowers IRR. A longer hold with stalled growth costs nearly seven points of IRR for the same dollars. The 7-year rows keep paydown at 30% for comparability. Two more years of amortization would lift both rows. Add-on borrowing in those years would cut them.
Sensitivity grid: growth against exit multiple
Hypothetical, our arithmetic. 5-year hold, 30% paydown, profits-interest pool, pari passu common. Each cell shows stake value, MOIC and IRR.
| Annual EBITDA growth | 9x exit | 10x exit | 11x exit |
|---|---|---|---|
| 0% (EBITDA stays $3.0M) | $6,552,000, 1.09x, 1.8% | $7,656,000, 1.28x, 5.0% | $8,760,000, 1.46x, 7.9% |
| 5% (exit EBITDA $3.83M) | $9,297,134, 1.55x, 9.2% | $10,706,148, 1.78x, 12.3% | $12,115,163, 2.02x, 15.1% |
| 10% (exit EBITDA $4.83M) | $12,618,027, 2.10x, 16.0% | $14,396,030, 2.40x, 19.1% | $16,174,033, 2.70x, 21.9% |
Read the grid by row. Within this grid, each five-point step in growth adds more value than a full turn of exit multiple. At 9x, moving from 5% to 10% growth adds $3.32 million, while moving from 9x to 10x at 10% growth adds $1.78 million. The ratio depends on leverage, hold length and starting multiple, so rerun the grid with your own inputs. A flat business falls short of an 8% IRR even at 11x, a turn above its entry price.
Set the growth input against the market. CMS National Health Expenditure data show U.S. physician and clinical services spending grew 8.1% to $1,109.7 billion in 2024, and CMS projects that category to grow 5.5% a year on average from 2025 to 2034. Spending growth is not EBITDA growth, but the comparison is useful. The 5% row sits near the projected pace for the category. The 10% base case needs add-ons, new sites, margin gains or share gains on top of it. Ask the sponsor to split its growth rate into those pieces.
Breakeven exit multiple: what it takes to get your $6 million back
Hypothetical, our arithmetic. 5-year hold, 30% paydown, 8% profits-interest pool with a $15 million threshold. Breakeven is the exit multiple at which your stake equals $6,000,000. The preferred rows use the 8% compounding preference from the waterfall section below.
| Your security | Flat EBITDA ($3.0M) | 5% growth ($3.83M) | 10% growth ($4.83M) |
|---|---|---|---|
| Pari passu common | 8.5x | 6.7x | 5.3x |
| Behind sponsor non-participating preferred | 10.0x | 7.9x | 6.2x |
| Behind sponsor participating preferred | 13.3x | 10.4x | 8.3x |
This table is the quickest test of a structure. Pari passu common with 10% growth gets its cost back at an exit just above half the 10x entry. Behind a participating preferred with flat EBITDA, you need an exit more than three turns above entry just to recover your $6 million.
4 things the calculator does not model, and how to adjust
Hypothetical, our arithmetic. Each adjustment starts from the base case above: 15,000,000 units at $1.00, 6,000,000 of them yours.
| Item | Effect on your stake | Adjustment | Base case effect |
|---|---|---|---|
| Profits interests above a threshold | Pool shares only in gains above the threshold | Effective pool % = pool % × (1 − threshold ÷ equity before pool) | 8% × (1 − $15.0M ÷ $42.6M) = 5.19% |
| Add-on funded with new equity above your entry price | Your ownership % falls | Ownership = your units ÷ total units after issuance | Sponsor adds $2,500,000 at $1.50 per unit = 1,666,667 new units, 16,666,667 total. Your 6,000,000 units = 36.0%. Stake $14,556,630, 2.43x, 19.4% IRR |
| Exit transaction fees | Banker, legal and other costs come off proceeds | Subtract fees from exit EV before debt, then apply the pool threshold | Fees 2% × $53,146,830 = $1,062,937. Equity before pool $41,583,893. Pool 8% × $26,583,893 = $2,126,711. Equity to capital holders $39,457,182. Your 40%: $15,782,873, 2.63x, 21.3% IRR |
| Dividend recap or interim distributions | Cash arrives early, exit debt rises | Model as a separate interim cash flow. The calculator's IRR assumes none | Raises IRR, lowers exit equity by the recap debt still outstanding |
The dilution row assumes the add-on bought with the new $2.5 million is already inside the 10% growth plan. Exit EV, exit debt and the $15 million threshold stay at base case, so exit equity to capital holders stays at $40,435,084 and only your share changes. That is the right test when the sponsor's growth rate already counts on acquisitions. Someone has to fund those acquisitions, and the choice of funding moves your stake.
| Funding for the same $2.5M add-on (inside the growth plan) | Exit debt | Equity to capital holders | Your ownership | Your stake | MOIC | IRR |
|---|---|---|---|---|---|---|
| Already funded from cash flow (base case) | $10,500,000 | $40,435,084 | 40.0% | $16,174,033 | 2.70x | 21.9% |
| New debt, still outstanding at exit | $13,000,000 | $38,135,084 | 40.0% | $15,254,034 | 2.54x | 20.5% |
| New sponsor equity at $1.50 per unit | $10,500,000 | $40,435,084 | 36.0% | $14,556,630 | 2.43x | 19.4% |
In the debt row, equity before pool is $40,146,830, and the pool takes 8% × $25,146,830 = $2,011,746. If an add-on lifts EBITDA above the base plan, exit equity rises and recovers part of either cost. Ask the sponsor which case its model uses and get pre-emptive rights so you can buy into new equity at the issue price.
Platforms grow by buying practices. Of the 1,029 PE-backed U.S. healthcare deals the Private Equity Stakeholder Project tracked in 2025, 664 were add-ons, 214 were growth investments and 151 were leveraged buyouts, a count PESP describes as likely an underestimate. Each add-on is funded with new debt, new equity or both. Run a 0% paydown case and a diluted case, and treat the base case as a ceiling until the sponsor shows its add-on funding plan.
Where your rollover sits in the waterfall
The calculator assumes one class of common equity. Many sponsor deals differ. The sponsor takes preferred units with an accruing return, or the rollover lands in a junior class, in a subsidiary below the holding company that gets sold, or in a holdco note. Each one changes the payout.
| Rollover structure | How it pays at the second sale | How to model it |
|---|---|---|
| Common, pari passu with sponsor | Pro rata with the sponsor from the first dollar | Use the calculator as is |
| Common behind sponsor non-participating preferred | Sponsor takes its accrued preference or converts to common, whichever pays it more | Run both paths below and use the lower result for you |
| Common behind sponsor participating preferred | Sponsor takes its preference, then also shares in the remainder as if converted | Cuts value in every case |
| Junior class or subsidiary-level equity | Paid after all senior classes and holdco debt | Subtract senior claims from exit equity before applying your % |
| Holdco note or seller note | Fixed interest and principal, no upside | Model as debt at its stated rate |
Worked example (hypothetical, our arithmetic): same deal, sponsor's $9 million held as 8% compounding preferred. The sponsor's preference after five years is $9,000,000 × 1.08^5 = $13,223,953. The weak case holds EBITDA flat at $3 million and exits at 9x. Distribution order:
- Exit EV pays the $10,500,000 of remaining debt.
- Profits interests take 8% of equity above the $15,000,000 threshold.
- Non-participating preferred: the sponsor compares its $13,223,953 preference with the 60% it would own if it converted, and takes the larger amount. If it takes the preference, it holds no common. Your units are then the only common, and you receive 100% of what is left. If it converts, you hold 40% of the common, the same as pari passu.
- Participating preferred: the sponsor takes its preference first. The remainder is then split 60% to the sponsor and 40% to you.
| Step | Base case (11x, 10% growth) | Weak case (9x, flat EBITDA) |
|---|---|---|
| Exit EV | $53,146,830 | $27,000,000 |
| Equity after debt | $42,646,830 | $16,500,000 |
| Profits interests | $2,211,746 | $120,000 |
| Equity to capital holders | $40,435,084 | $16,380,000 |
| Sponsor's 60% if it converts | $24,261,050 | $9,828,000 |
| Remainder after the $13,223,953 preference, before any split | $27,211,131 | $3,156,047 |
| Participating case: sponsor's 60% of that remainder | $16,326,679 | $1,893,628 |
| Participating case: your 40% of that remainder | $10,884,452 | $1,262,419 |
| Your security | Your base case stake | MOIC | Your weak case stake | MOIC |
|---|---|---|---|---|
| Pari passu common (40% of equity to capital holders) | $16,174,033 | 2.70x | $6,552,000 | 1.09x |
| Behind non-participating preferred | $16,174,033 (sponsor converts, you take 40%) | 2.70x | $3,156,047 (sponsor takes preference, you take 100% of the remainder) | 0.53x |
| Behind participating preferred (you take 40% of the remainder) | $10,884,452 | 1.81x | $1,262,419 | 0.21x |
In the base case the non-participating sponsor converts, because $24,261,050 beats its $13,223,953 preference. The structure costs you nothing there. In the weak case conversion would pay the sponsor only $9,828,000, so it takes the preference and leaves you the $3,156,047 remainder. A participating sponsor takes its preference and 60% of what is left in both cases, which is why it costs you $5.29 million even in the base case. Some LLC agreements pay profits interests only after the preference is returned. In that order the pool comes out of the common's share, and your weak case figures fall further. Get the capitalization table and the distribution waterfall from the draft LLC agreement before trusting any output. The Physician Rollover Equity Checklist lists the questions to ask.
Choosing the exit multiple
The exit multiple is the sponsor's call and the market's price. Three datasets bear on it. Each measures a different population and period, so read them separately and do not average across them.
| Dataset | Population and period | Figures |
|---|---|---|
| PitchBook, reported by Sikich (Q3 2026) | Healthcare M&A deals with reported multiples, 2024 to Q3 2026 | Median EV/EBITDA 14.5x (2024), 13x (2025), 11.6x (2026 through Q3) |
| PitchBook, reported by Sikich (Q3 2026) | PE-backed U.S. healthcare services buyouts, 2024 and 2025 | Median 13.5x (2024), 13.6x (2025) |
| Buckhead FMV | 187 U.S. healthcare services control deals with primary-source prices, January 2023 to October 2026. EBITDA medians come from only 68 deals with positive EBITDA across all four years | Median 11.4x (2023), 9.7x (2024), 6.5x (2025), 9.1x (2026 through October) |
Buckhead describes its yearly medians as "a band, not a trend" and attributes the 2025 dip to a smaller, more mid-market deal mix rather than a broad repricing. With 68 EBITDA observations over four years, each annual median rests on a small sample. Buckhead also notes its EBITDA medians lean toward larger deals, because large and public-company deals report EBITDA more often. Use the Buckhead band as a check on the downside case, not as a point estimate. Owners who roll because they expect better pricing later should put that view in an upside case.
Size is the stronger argument for a higher exit multiple. The worked example is a dental platform, so the relevant Sikich range is 9 to 11x for DSO platforms. That makes 11x the top of the range, not the middle. Sikich's indicative physician practice bands (Q3 2026) show how steep the size premium runs:
| Practice EBITDA | Indicative EV/EBITDA (Sikich, Q3 2026) |
|---|---|
| Below $1 million | 5 to 7x |
| $1 million to $3 million | 7 to 9x |
| $3 million to $5 million | 9 to 11x |
| Above $5 million | 11 to 13x |
The base case grows EBITDA from $3.0 million to $4.8 million. Two more years at 10% reach $5.8 million, which falls in the above-$5 million band. Size moves the range. Specialty, growth rate, payer mix, customer concentration and deal structure set where a business lands inside it. Segment benchmarks are in Healthcare Valuation Multiples by Sector and Specialty.
Timing: who buys at the second sale
Exit windows open and close, and IRR pays for every extra year. Bain & Company's Global Healthcare Private Equity Report 2026 puts global healthcare PE exit value at an expected $156 billion in 2025, up from $54 billion in 2024. Bain expected more than 150 sponsor-to-sponsor deals in 2025, worth more than $120 billion. Of the 26 North American healthcare PE deals above $1 billion through November 2025, more than 70% were sponsor-to-sponsor sales. The second buyer can also be a strategic. Bain cites Cencora's acquisition of Retina Consultants of America from Webster Equity Partners and Cardinal Health's GI Alliance acquiring Solaris Health from Lee Equity Partners.
Many physician rollover holders are mid-hold now. In the AMA's 2024 Physician Practice Benchmark Survey, 6.5% of U.S. physicians worked in PE-owned practices, up from about 4.5% in 2020 and 2022, and 38% of those said their practice had been acquired in the past five years.
Regulatory review at the second sale can lengthen the hold. Some states review certain healthcare transactions, as Latham & Watkins' 2026 state regulatory review describes, and these rules change. Ask your attorney which reviews could apply to your deal. Any added time lowers IRR at the same exit value. In the base case, one extra year with no growth takes IRR from 21.9% to 18.0%. Our healthcare M&A process guide covers how reviews affect timing.
Tax: compare offers after tax
The calculator shows pre-tax values. Deferral is what makes rollover efficient. Rollovers are commonly structured to defer tax on the rolled portion until the second sale, while the cash portion is taxed at closing. Deferral is not automatic. The holding company's tax classification, any cash or debt relief you receive in the exchange and how the contribution is documented all affect the result. Ask the buyer for its structure memo early and model both cases until the treatment is settled.
A taxable roll costs less than it first appears, because the tax you pay at close gives you basis in the rolled units. That basis cuts the gain at the second sale.
Worked example (hypothetical, our arithmetic). Base case stake of $16,174,033. Assumptions, not market data: zero starting basis in the rolled practice equity, and a single 25% combined rate at both dates.
| Deferred roll | Roll taxable at close | |
|---|---|---|
| Tax at close | $0 | $1,500,000 |
| Basis in rolled units | $0 | $6,000,000 |
| Gain at second sale | $16,174,033 | $10,174,033 |
| Tax at second sale (25%) | $4,043,508 | $2,543,508 |
| Total tax paid | $4,043,508 | $4,043,508 |
| Net after tax at second sale | $12,130,525 | $13,630,525 |
Total tax is the same. The taxable roll costs you two things. First, you pay $1.5 million five years early, out of your cash proceeds, on equity you cannot sell. At an 8% opportunity rate, that timing costs $1.5 million × (1.08^5 − 1) = $703,992. Second, rates can change between close and exit, in either direction. In a downside case the taxable roll also leaves a capital loss if the stake ends below its $6 million basis, and that loss is worth only what you can offset with other gains.
Sizing the roll: cash at close against the stake at exit
The rollover amount is often the one input you can still move. On the same $30 million deal, every dollar you roll is a dollar of sponsor cash you do not receive at close. Assume you own 100% of the practice, carry no existing debt and pay no fees, so your cash at close is the $30 million price less your roll. The entry equity stays at $15 million and the pool threshold stays at $15 million, so only your ownership share changes.
Hypothetical, our arithmetic. Pari passu common, 5-year hold, 30% paydown, pre-tax. Base case is 11x and 10% growth. Weak case is 9x and flat EBITDA.
| Rollover amount | Share of price | Cash at close | Ownership | Base case stake | Base case total (cash plus stake) | Weak case stake | Weak case total (cash plus stake) |
|---|---|---|---|---|---|---|---|
| $3,000,000 | 10% | $27,000,000 | 20% | $8,087,017 | $35,087,017 | $3,276,000 | $30,276,000 |
| $6,000,000 | 20% | $24,000,000 | 40% | $16,174,033 | $40,174,033 | $6,552,000 | $30,552,000 |
| $9,000,000 | 30% | $21,000,000 | 60% | $24,261,050 | $45,261,050 | $9,828,000 | $30,828,000 |
Three readings follow from the table:
- In pari passu common the downside is mild. Rolling $9 million instead of $3 million adds about $10.2 million in the base case and still adds about $550,000 in the weak case, because the weak case MOIC is 1.09x, just above cost.
- The waterfall changes that picture. Behind a participating preferred, the $6 million roll's weak case stake falls to $1,262,419, and the weak case total drops to about $25.3 million. A larger roll into a junior security puts more of the price at risk, not just more of the upside.
- Liquidity sets the ceiling. Size the roll so that cash at close covers personal debts, tax on the cash portion and several years of spending without counting on the second sale. The rest is the amount you can afford to leave in for five to seven years.
Use the calculator to rerun this table with your own price, debt and structure before you agree a rollover percentage in the LOI.
Legal areas that touch the rolled stake
Three areas bear directly on rollover equity. If you will refer patients to a platform you partly own, federal referral and self-referral rules may affect that ownership, so ask your attorney how they apply to your deal. HHS OIG and CMS publish background on these rules. Corporate practice of medicine and dentistry rules shape whether you hold equity in the practice entity, the MSO or a holding company above both. The units you receive are securities, so offering rules govern how they are issued to you. Have your attorney look into each one for your deal. Our guides on healthcare compliance due diligence and physician investors who refer cover the business side.
The rollover data room: 7 documents to request before you sign
Every number in the calculator should trace to a document the sponsor has given you. If a document is missing, the matching input is a guess. Ask for these before exclusivity ends.
| Document | Calculator input it supports | What to check in it | Worked example figure (hypothetical) |
|---|---|---|---|
| Sources and uses table | Debt at close, entry equity | Debt, sponsor cash and rollover add up to the price plus fees | $15M debt, $9M sponsor cash, $6M roll |
| Pro forma capitalization table | Ownership % | Total units at close, including co-investor, management and fee-funded units | 6,000,000 of 15,000,000 units, 40% |
| Draft LLC agreement | Waterfall position | Your unit class, any sponsor preference, its rate and whether it participates, and where the pool is paid | Pari passu common 2.70x, behind a participating preferred 1.81x |
| Incentive plan term sheet | Management pool | Pool size, threshold mechanics, vesting and what happens to forfeited units | 8% pool above a $15M threshold, 5.19% effective |
| Credit agreement summary | Debt paid down by exit | Required amortization, cash sweep and room to borrow more for add-ons | 30% paydown. At 0% paydown the stake falls to $14.52M |
| Sponsor's base case model | Growth, years to sale, exit multiple | Which add-ons are inside the growth rate and how each is funded | 10% growth, 5 years, 11x |
| Fund vintage and remaining term | Years to second sale | How many years the fund has left and whether extensions are likely | A 7-year hold with flat growth drops IRR from 21.9% to 15.2% |
Two free public checks add to the packet. Search the sponsor's fund name in SEC EDGAR full-text search. Form D notices show when a private fund began raising, which dates the fund's vintage and the pressure it faces to sell. If a banker is running the sale, look up the firm and the individual bankers in FINRA BrokerCheck for registration and disclosure history.
Then run three cases rather than one. Enter the sponsor's model as given. Rerun it at 0% paydown with the diluted ownership from any planned add-on equity. Find your structure's row in the breakeven table and compare it with the entry multiple. If the three cases tell different stories, the gap is what you are negotiating over.
What to negotiate before you roll: 8 terms
A minority rollover holder does not control the second sale. The LLC agreement decides whether you receive the sponsor's price, on the sponsor's terms, at the sponsor's time. These eight terms carry most of the value modeled above:
- [ ] Same security as the sponsor. Common alongside common, at the same unit price.
- [ ] Written waterfall. The exact distribution order, including where preferred returns and the management pool sit.
- [ ] Pool size, threshold, vesting and forfeiture. Profits interests with a threshold at entry value take far less of your stake than a flat pool. Forfeited and unvested units should return to all holders, not be reissued at the sponsor's discretion.
- [ ] Tag-along rights. You sell at the same price and terms when the sponsor sells.
- [ ] Drag-along limits. The sponsor can force a sale only for the same per-unit consideration it receives.
- [ ] Pre-emptive rights. The right to buy into new equity issuances so add-on funding does not dilute you.
- [ ] Repurchase terms. The price that applies if you leave, retire or are terminated, and a narrow definition of "cause."
- [ ] Information rights. Quarterly financials and the annual valuation mark, so you can rerun this calculator each year.
Raise every missing term at the LOI stage. Terms are hardest to change after exclusivity. The LOI and Term Sheet Red Flags checklist covers the language to look for.
Roll more or roll less: a decision table
| Factor | Supports rolling more | Supports rolling less |
|---|---|---|
| Security | Same class and price as sponsor | Junior class, or behind sponsor preferred |
| Breakeven exit multiple | Well below the entry multiple | At or above the entry multiple |
| Growth plan | Funded add-on pipeline with your practice as an anchor | Growth depends on acquisitions not yet identified |
| Add-on funding | Debt or cash flow, with pre-emptive rights on any new equity | New equity issued without your right to participate |
| Sponsor timing | Early in the fund's life, with room to hold for growth | Late in the fund's life, with pressure to sell on a set date |
| Tax | Deferral confirmed in the structure memo | Roll taxable at close and paid from your cash proceeds |
| Your liquidity | Cash at close covers taxes, debt and personal needs | You need the rolled dollars within the hold period |
| Information rights | Quarterly financials and annual marks | No reporting commitment |
| Your role after close | You drive EBITDA growth at the platform | You plan to reduce clinical time or leave |
Run the breakeven table first. If your structure needs an exit above entry just to return your cost, the roll is a bet on multiple expansion and should be sized like one.
Rollover compared with the other deferred pieces of price
| Deferred component | What drives the payout | Upside cap |
|---|---|---|
| Rollover equity | Platform EBITDA, exit multiple, debt, waterfall | None |
| Earnout | Your practice hitting set targets | Fixed maximum |
| Escrow or holdback | Indemnity claims during the survival period | Amount held |
Earnouts are more common than they were. SRS Acquiom's 2026 study found U.S. private equity buyers in its deal data used earnouts in 24% of 2025 deals, up from 13% in 2014 to 2022. A rollover and an earnout in the same offer put two layers of price at risk.
Next step: pair this with the proceeds calculator
This page values the stake you keep. The Healthcare Deal Proceeds Calculator shows the cash you take home at close after debt payoff, escrow, fees and the rollover itself. Run both on the same offer to compare cash now with value later. If the headline price is still open, start with the Practice Valuation Calculator. For how rollover sits alongside earnouts and MSO structures, read Healthcare Deal Structures.
Questions owners ask about rollover equity
Is rollover equity worth the same as the cash portion of the price?
No. Cash at close is certain and paid now. Rollover is an illiquid minority stake. Its value depends on EBITDA growth, the exit multiple, remaining debt, dilution, where your security sits in the waterfall and when the sponsor decides to sell. It can return several times its entry value or close to nothing. Treat rolled dollars as a private equity investment you make alongside the buyer.
What rollover percentage is typical in healthcare deals?
No public dataset reports a reliable median, so anchor on structure and size. FOCUS Investment Banking's 2026 dermatology benchmarks show platform-ready dermatology practices, typically with $5 million or more of EBITDA, often receiving 70% or more of the price in cash at close, with meaningful rollover. That leaves roughly 30% or less of the price for rollover and any other deferred pieces. Measure your roll two ways. In this page's example, $6 million is 20% of the $30 million price but 40% of the $15 million entry equity, and the second figure sets your ownership.
What if my rollover is not in the same security as the sponsor's equity?
Then the calculator overstates your value. In this page's hypothetical, a sponsor 8% non-participating preferred cuts your $6 million roll from $6.55 million to $3.16 million in the weak case. A participating preferred cuts your stake in the base case too, from $16.17 million to $10.88 million. If the rollover is a holdco note or seller note, model it as debt with a fixed return, not as equity.
Is the rolled portion taxed at closing?
Often not. Rollovers are commonly structured to defer tax on the rolled portion until the second sale, while the cash portion is taxed at closing. Deferral is not automatic. The entity type, the cash and debt in the exchange and how the contribution is built all affect it. If the roll is taxable, you take a matching basis in the rolled units, so most of the early tax comes back as lower tax at the second sale. The real cost is paying cash now on equity you cannot sell, plus the time value of that cash.
How does the management incentive pool reduce my rolled stake?
Sponsors reserve equity for executives and key physicians, usually as profits interests or options. Profits interests generally share only in value above a threshold set when they are granted. In this page's base case, an 8% pool sharing in value above a $15 million threshold takes $2.21 million, or 5.19% of exit equity, not 8%. Ask for the pool size, the threshold mechanics, the vesting terms and where the pool sits in the waterfall.
What exit multiple should I enter?
Start with the entry multiple and run a case one to two turns lower. PitchBook's median healthcare M&A multiple, reported by Sikich, fell from 14.5x in 2024 to 11.6x in 2026 through the third quarter. Buckhead FMV's yearly medians for U.S. healthcare services control deals moved in a band between 6.5x and 11.4x from 2023 to October 2026, on small annual samples. Count multiple expansion as upside unless EBITDA growth moves the business into a higher size band.
Sources
- CMS, National Health Expenditure Fact Sheet, 2024 data and 2025 to 2034 projections
- SEC EDGAR full-text search
- FINRA BrokerCheck
- HHS Office of Inspector General
- CMS, Physician Self-Referral
- AMA, Physician Practice Characteristics in 2024
- Buckhead FMV, Healthcare Services M&A Valuation Multiples 2023 to 2026, data through October 2026
- Sikich, Q3 2026 US Healthcare M&A Market Update reporting PitchBook data, Q3 2026
- Bain & Company, Global Healthcare Private Equity Report 2026 press release, 2025 data
- Bain & Company, New Models of Value Creation for Physician Groups, 2026
- FOCUS Investment Banking, Dermatology Practice Valuation: 2026 Benchmarks
- Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review, PitchBook and LevinPro HC data
- Latham & Watkins, US State Regulatory Spotlight on Healthcare Transactions: Reflections From 2026
- SRS Acquiom, 2026 M&A Earnout and Milestone Trends, 2025 data